At Princess Margaret Cancer Centre in Toronto, a five-year study called SHERLOCK is enrolling 7,000 cancer survivors in a search for something medicine has long struggled to offer: certainty. By drawing blood repeatedly and scanning it for microscopic traces of tumor DNA invisible to conventional imaging, researchers hope to learn whether this knowledge can guide treatment — sparing some patients from unnecessary therapies while catching recurrence in others before it takes hold. It is, at its core, a wager that better information is more merciful than the silence that follows a clean scan.
Blood test trial aims to detect cancer recurrence before it happens
Cancer patients experience significant psychological burden from recurrence fears during follow-up appointments; some experience treatment side effects that could be avoided with accurate early detection.
When will I actually be free from this fear?
Mark
Why does this trial need to be so large? Couldn't smaller studies already tell us if the blood test works?
Mimi
Smaller studies show the pattern—people with cancer DNA in their blood tend to relapse. But "tend to" is not good enough for medicine. You need thousands of patients followed for years to know if the test actually changes outcomes, if it saves lives or just creates false alarms.
Mark
So right now, doctors can't use this test to decide treatment?
Mimi
Correct. It's not standard of care yet. It's promising, but promising is not the same as proven. That's what SHERLOCK is for—to build the evidence.
Mark
What happens to a patient if their blood test is positive? Do they automatically get more treatment?
Mimi
Not automatically. They could be offered experimental immunotherapies as part of a trial. But the whole point is to figure out whether that actually helps them, or whether it's just more treatment with more side effects.
Mark
And if the test is negative?
Mimi
That's where it gets interesting. A negative test might finally let doctors say, "You're done. No more chemotherapy, no more radiation." That could spare people from years of cumulative damage.
Mark
Paul Lonergan's story—he got the experimental drug and it worked. Doesn't that prove the concept?
Mimi
It's one person's story, and it's real and important. But one success doesn't tell you how often it works, who it works for, or whether the benefit outweighs the risks. That's why you need 7,000 patients and five years.
O Pulso
- Cancer survivors carry a quiet, persistent dread between follow-up appointments — a fear that no clear scan can fully extinguish.
- Liquid biopsies can detect residual tumor DNA too small for CT scans to find, but whether acting on that information actually improves outcomes remains unproven.
- SHERLOCK will test two high-stakes interventions: offering experimental immunotherapy to patients with detectable cancer DNA, and allowing those without it to stop treatment and avoid cumulative side effects.
- A bladder cancer researcher cautions that this is an observational study — a necessary step toward the clinic, but not yet a clinical tool.
- One patient, Paul Lonergan, already enrolled in a predecessor trial and received immunotherapy after his blood tested positive post-treatment; three years on, he is cancer-free and back on the ice.
At Princess Margaret Cancer Centre in Toronto, a five-year study called SHERLOCK is enrolling 7,000 cancer survivors in a search for something medicine has long struggled to offer: certainty. By drawing blood repeatedly and scanning it for microscopic traces of tumor DNA invisible to conventional imaging, researchers hope to learn whether this knowledge can guide treatment — sparing some patients from unnecessary therapies while catching recurrence in others before it takes hold. It is, at its core, a wager that better information is more merciful than the silence that follows a clean scan.
At Princess Margaret Cancer Centre in Toronto, researchers are launching SHERLOCK, one of the largest trials ever designed to answer the question that shadows every cancer survivor: Is it really gone?
The trial will enroll 7,000 patients who have completed treatment, drawing their blood repeatedly over five years to search for traces of tumor DNA too small for CT scans to detect. These liquid biopsies have shown promise in earlier, smaller studies, but whether they can meaningfully change how doctors treat patients — or how patients live with fear — remains unknown. Lead investigator Dr. Lillian Siu frames the stakes plainly: a positive result could trigger experimental immunotherapy before disease returns; a negative result could finally justify stopping treatment, sparing patients from unnecessary side effects.
The science of molecular residual disease has been developing for a decade, and the pattern in the data is consistent — detectable cancer DNA in the blood strongly predicts relapse. But correlation is not clinical readiness, and that gap is precisely what SHERLOCK is designed to close. Siu says she watches her patients' faces at follow-up appointments and sees the fear that never fully leaves them, even after curative treatment.
Gillian Vandekerkhove, a liquid biopsy researcher at UBC, welcomes the trial's breadth but urges measured expectations. The study will generate invaluable data across cancer types, she says, but additional trials will be needed before the test moves into routine care.
The human stakes are already visible in Paul Lonergan, a 68-year-old Toronto man who was diagnosed with throat cancer after coughing up blood at a hockey game. After treatment at Princess Margaret, he enrolled in a related trial, tested positive for residual cancer DNA, and received an experimental immunotherapy. Three checkups later, he remains cancer-free — still struggling to swallow, still drinking smoothies, but back on the ice. The $50 million SHERLOCK trial, funded by the Peter Gilgan Foundation, is a bet that what patients need most is not reassurance, but answers.
At Princess Margaret Cancer Centre in Toronto, researchers are launching one of the largest trials yet to answer a question that haunts nearly every cancer survivor: Is it really gone?
The study, called SHERLOCK, will enroll 7,000 patients who have finished their radiation, chemotherapy, or other cancer treatments. Researchers will draw their blood repeatedly over five years, searching for traces of tumor DNA so small that standard CT scans cannot find them. This kind of test—a liquid biopsy—has shown promise in smaller studies around the world, but nobody yet knows whether it will actually change how doctors treat cancer or how patients live with the fear of recurrence.
Dr. Lillian Siu, the lead investigator and scientific director of the hospital's Peter Gilgan Centre for Early Cancer Detection Research, explains the logic clearly. If a patient's blood test comes back positive for residual cancer DNA, they could receive experimental immunotherapies designed to stop the disease before it returns. If the test is negative, it might finally give patients permission to stop treatment—sparing them from the cumulative damage of unnecessary chemotherapy or radiation. The trial will also examine whether the test works equally well across different cancer types, a question that has largely gone unanswered.
The science is not new. Researchers have been studying molecular residual disease—the microscopic remnants left behind after treatment—for about a decade. What has changed is the accumulation of evidence. When blood samples are matched against actual patient outcomes, the pattern becomes clear: people with detectable cancer DNA in their blood have a very high likelihood of relapse. But "very likely" is not the same as "certain," and "promising" is not the same as "ready for the clinic." That is why SHERLOCK exists. That is why it will take five years.
Siu is acutely aware of what drives this research beyond the data. She watches her patients' faces during follow-up appointments. "Most patients, even after curative treatment, whenever they come back to the clinic for a followup, I can see that they have fear in their eyes," she said. They exhale when their scans are clear, only to feel the anxiety rebuild before the next appointment. The question that never quite leaves them is: when will I actually be free from this fear?
Gillian Vandekerkhove, a bladder cancer researcher at the University of British Columbia who studies liquid biopsies, welcomes SHERLOCK's breadth. Most research has focused narrowly on specific cancer types; this trial will generate data and biological samples that researchers across Canada and beyond can continue to mine for years. But she is careful about expectations. "This is an observational study," she said. "It's going to help us understand the technology better and the best-use cases, but there will need to be additional trials. This is not something we're ready to move into the clinic."
Paul Lonergan, a 68-year-old from Toronto, has already lived the promise of this research. Three years ago, he was diagnosed with throat cancer after coughing up blood during a hockey game—a symptom his family doctor had initially dismissed as a virus. After radiation and chemotherapy at Princess Margaret, he enrolled in a different trial called MERIDIAN, which tested for residual cancer in head and neck patients. His tumor was gone, but his blood contained cancer fragments. He received an experimental immunotherapy drug. "Sure as heck it worked," he said. Three six-month checkups later, he remains cancer-free. He still struggles to swallow and drinks smoothies instead of solid food, but he is back on the ice, moving slowly and carefully, grateful simply to be playing.
The SHERLOCK trial is funded by a $50 million donation from the Peter Gilgan Foundation. It represents a bet that the fear cancer patients carry can be addressed not by reassurance alone, but by better information—by a test that might finally answer the question that keeps them awake at night. Whether that bet pays off will take years to know.
Citações Notáveis
Most patients, even after curative treatment, whenever they come back to the clinic for a followup, I can see that they have fear in their eyes.— Dr. Lillian Siu, lead investigator
This is an observational study. It's going to help us understand the technology better, but there will need to be additional trials. This is not something we're ready to move into the clinic.— Gillian Vandekerkhove, University of British Columbia researcher
Quer a matéria completa?
Leia o original em Sudbury News ↗
Health & Medicine